Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma

Histopathology

Volumn 44, Issue 4, 2004, Pages 323-331

  Pinto De Sousa, J ^a,b   Silva, F ^a   David, L ^a   Leitao D ^a   Seixas, M ^a   Pimenta, A ^a   Cardoso De Oliveira, M ^a  

^a University of Porto   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Gastric carcinoma; Immunohistochemistry; p53; Prognosis; Survival

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STOMACH CARCINOMA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1842844370     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2004.01852.x     Document Type: Article

References (83)

1. Siewert JR, Sendler A. The current management of gastric cancer, Adv. Surg. 1999; 33; 69-93.
2. Blot W, Devesa S, Kneller R, Fraumeni J. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265; 1287-1289.
3. Lacueva FJ, Calpena R, Medrano J et al. Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53. Cancer 2000; 89; 21-28.
4. Siewert JR, Fink U, Sendler A et al. Gastric cancer. Curr. Probl. Surg. 1997; 43; 837-937.
5. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer H. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72; 2089-2097.
6. Fink U, Stein HJ, Schumacher C, Wilke H. Neoadjuvant chemotherapy for gastric cancer; update. World. J. Surg. 1995; 19; 509-516.
7. Schumacher C, Fink U, Becker K et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxirubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001; 91; 918-927.
8. Albino AP, Jacne J, Altorki NK et al. Amplification of HER-2/neu gene in human gastric cancer: correlation with primary site. Eur. J. Surg. Oncol. 1995; 21; 56-60.
9. Allgayer H, Heiss M, Schildberg F. Prognostic factors in gastric cancer. Br. J. Surg. 1997; 84; 1651-1664.
10. Pinto-de Sousa J, David L, Almeida R et al. c-erb B-2 expression is associated with tumour location and venous invasion and influences survival of patients with gastric carcinoma. Int. J. Surg. Pathol. 2002; 10; 247-256.
11. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 1998; 83; 1094-1101.
12. Steele R, Thompson A, Hall P, Lane D. The p53 tumour suppressor gene. Br. J. Surg. 1998; 85; 1460-1467.
13. Wong S, Seow-Choen F, Leong A, Ho Y, Aw S. Mutant plasma p53 protein levels: prognostications in colorectal carcinoma. Br. J. Surg. 1997; 84; 664-665.
14. Yao J, Goh H, Smith D. p53 mutations in primary colorectal adenocarcinomas and liver metastases. Br. J. Surg. 1996; 83; 1245-1246.
15. Hamada M, Fujiwara T, Hizuta A et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol 1996; 122; 360-365.
16. Bosari S, Viale G, Bossi P et al. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J. Natl Cancer Inst. 1994; 86; 681-687.
17. Reed W, Hannisdal E, Boehler P, Gundersen S, Host H, Marthin J. The prognostic value of p53 and c-erb B-2 immunostaining is overrrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 2000; 88; 804-813.
18. Billo P, Marchegiani C, Capella C, Sessa F. Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa. Pathologica 2000; 92; 249-256.
19. Duhaylongsod F, Gottfried M, Iglehart J, Vaughn A, Wolfe W. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann. Surg. 1995; 221; 677-683.
20. Hashimoto N, Tachibana M, Dhar DK, Yoshimura H, Nagasue N. Expression of p53 and RB proteins in squamous cell carcinoma of the esophagus: their relationship with clinicopathologic characteristics. Ann. Surg. Oncol. 1999; 6; 489-494.
21. Maehara Y, Kakeji Y, Watanabe A et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999; 85; 302-308.
22. Maehara Y, Tomoda M, Hasuda S et al. Prognostic value of p53 protein expression for patients with gastric cancer - a multivariate analysis. Br. J. Cancer 1999; 79; 1255-1261.
23. Seruca R, David L, Holm R et al. P53 mutations in gastric carcinomas. Br. J. Cancer 1992; 65; 708-710.
24. Roviello F, Marrelli D, Vindigni C, De Stefano A, Spina D, Pinto E. P53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type. Ann. Surg. Oncol. 1999; 6; 739-745.
25. Ireland A, Clark G, DeMeester T. Barrett's esophagus: the significance of p53 in clinical practice. Ann. Surg. 1997; 225; 17-30.
26. Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ, Chen KM. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br. J. Surg. 1998; 85; 1138-1142.
27. Gurel S, Dolar E, Yerci O et al. Expression of p53 protein and prognosis in gastric carcinoma. J. Int. Med. Res. 1999; 27; 85-89.
28. McCulloch P, Taggart T, Ochiai A, O'Dowd G, Nash J, Sasako M. c-erbB2 and p52 expression are not associated with stage progression of gastric cancer in Britain and Japan. Eur. J. Surg. Oncol. 1997; 23; 304-309.
29. Hosaka N, Ichikawa T, Nagashima Y et al. Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensitivity test in gastric and colon cancer. Anticancer Res. 2001; 21; 229-235.
30. Itaya M, Yoshimoto J, Kolima K, Futagawa S. Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors. Oncol. Report 1999; 6; 675-682.
31. Kikuyama S, Inada T, Shimizu K, Miyakita M, Ogata Y. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced recurrent gastric cancer. Anticancer Res. 2001; 21; 2149-2153.
32. Nakata B, Chung K, Ogawa M et al. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg. Today 1998; 28; 595-598.
33. Laurén P. The two histological main types of gastric carcinoma: diffuse and the so-called intestinal-type carcinoma. Acta Path. Microbiol. Scand. 1965; 64; 31-49.
34. Ming S. Gastric carcinoma: a pathobiological classification. Cancer 1977; 39; 2475-2485.
35. Sobin L, Wittekind C eds. TNM classifications of malignant tumours. International Union Against Cancer. New York: John Willey and Sons, 1997; 59-62.
36. Pinto-de-Sousa J, David L, Seixas M, Pimenta A. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig. Surg. 2001; 18; 102-110.
37. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53; 457-481.
38. Cox D. Regression models and life-tables. J. R. Stat. Soc. B 1972; 34; 187-220.
39. Tahara E. Molecular biology of gastric cancer. World J. Surg. 1995; 19; 484-490.
40. Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int. J. Cancer 1996; 69; 200-204.
41. Xiangming C, Hokita S, Natsugoe S et al. p21 expression is a prognostic factor in patients with p53-negative gastric cancer. Cancer Lett. 2000; 148; 181-188.
42. Kim JH, Uhm HD, Gong SJ et al. Relationship between p53 overexpression and gastric cancer progression. Oncology 1997; 54; 166-170.
43. Baldus SE, Schneider PM, Monig SP et al. p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status. Scand. J. Gastroenterol. 2001; 36; 975-980.
44. Chen BF, Marrogi AJ, Freeman SM, Clejan S. Gastric carcinoma: recent issues in prognostic factors. J. La State Med. Soc. 1995; 147; 138-145.
45. Craanen ME, Blok P, Dekker W, Offerhaus GJ, Tytgat GN. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995; 36; 848-852.
46. Diez M, Medrano MJ, Gutierrez A et al. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res. 2000; 20; 3929-3933.
47. Flejou JF, Muzeau F, Potet F, Lepelletier F, Fekete F, Henin D. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. Pathol. Res. Pract. 1994; 190; 1141-1148.
48. Gomyo Y, Ikeda M, Osaki M et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997; 79; 2067-2072.
49. Gomyo Y, Osaki M, Kaibara N, Ito H. Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int. J. Cancer 1996; 66; 594-599.
50. Hongyo T, Buzard GS, Palli D et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res. 1995; 55; 2665-2672.
51. Kaye PV, Radebold K, Isaacs S, Dent DM. Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter- relationship or correlation with prognosis. Eur. J. Surg. Oncol. 2000; 26; 39-43.
52. Liu XP, Tsushimi K, Tsushimi M et al. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol. Int. 2001; 51; 440-444.
53. Maeda K, Kang SM, Onoda N et al. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology 1998; 55; 594-599.
54. Muller W, Borchard F. Prognostic influence of p53 expression in gastric cancer. J. Pathol. 1996; 178; 255-258.
55. Ogawa M, Onoda N, Maeda K et al. A combination analysis of p53 and p21 in gastric carcinoma as a strong indicator for prognosis. Int. J. Mol. Med. 2001; 7; 479-483.
56. Starzynska T, Markiewski M, Domagala W et al. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996; 77; 2005-2012.
57. Wang JY, Lin SR, Hsieh JS, Hsu CH, Huang YS, Huang TJ. Mutations of p53 gene in gastric carcinoma in Taiwan. Anticancer Res. 2001; 21; 513-520.
58. Sanz-Ortega J, Steinberg SM, Moro E et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53. c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol. Histopathol. 2000; 15; 455-462.
59. Shiao YH, Palli D, Caporaso NE et al. Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol. Biomarkers Prev. 2000; 9; 631-633.
60. Baba M, Konno H, Maruo Y et al. Relationship of p53 and vascular endothelial growth factor expression of clinicopathological factors in human scirrhous gastric cancer. Eur. Surg. Res. 1998; 30; 130-137.
61. Ikeguchi M, Oka S, Saito H et al. Nuclear accumulation of p53 protein in gastric cancer strongly correlates with enlargement of nuclear area of cancer cells. Oncol. Report 2000; 7; 579-584.
62. Polkowski W, van Sandick J, Offerhaus G et al. Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann. Surg. Oncol. 1999; 6; 290-297.
63. Iwamatsu H, Nishikura K, Watanabe H et al. Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma. Gastric Cancer 2001; 4; 20-26.
64. Tang H, Hokita S, Che X et al. Comparison of p53 expression in proximal and distal gastric cancer: histopathologic correlation and prognostic significance. Ann. Surg. Oncol. 1997; 4; 470-474.
65. Flejou JF, Gratio V, Muzeau F, Hamelin R. p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. Mol. Pathol. 1999; 52; 263-268.
66. Rugge M, Shiao YH, Busatto G et al. The p53 gene in patients under the age of 40 with gastric cancer: mutation rates are low but are associated with a cardiac location. Mol. Pathol. 2000; 53; 207-210.
67. Tanière P, Martel-Planche G, Maurici D et al. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am. J. Pathol. 2001; 158; 33-40.
68. Siewert JR, Bottcher K, Stein HJ, Roder JD, Busch R. Problem of proximal third gastric carcinoma. World. J. Surg. 1995; 19; 523-531.
69. Sakaguchi T, Watanabe A, Sawada H et al. Characteristics and clinical outcome of proximal-third gastric cancer. J. Am. Coll. Surg. 1998; 187; 352-357.
70. Ranzani G, Luinetti O, Padovan L et al. p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol. Biomarkers Prevention 1995; 4; 223-231.
71. Vollmers HP, Dammrich J, Hensel F et al. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma. Cancer 1997; 79; 433-440.
72. Nakajima M, Sawada H, Yamada Y et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85; 1894-1902.
73. Orita H, Maehara Y, Emi Y et al. c-erb B-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. Hepatogastroenterology 1997; 44; 294-298.
74. Tsugawa K, Yonemura Y, Hirono Y et al. Amplification of the c-met, c-erb B-2 and epidermal growth factor gene in human gastric cancers: correlation to clinical features. Oncology 1998; 55; 475-481.
75. Uchino S, Tsuda H, Maruyama K et al. Overexpression of c-erb B-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993; 72; 3179-3184.
76. Kasper HU, Schneider-Stock R, Mellin W, Gunther T, Roessner A. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. Pathol. Res. Pract. 1999; 195; 815-820.
77. Danesi DT, Spano M, Fabiano A et al. Flow cytometric DNA ploidy. p53, PCNA, and c-erbB-2 protein expressions as predictors of survival in surgically resected gastric cancer patients. Cytometry 2000; 42; 27-34.
78. Boku N, Chin K, Hosokawa K et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluouracil and cis-platinum. Clin. Cancer Res. 1998; 4; 1469-1474.
79. Cascinu S, Graziano F, Del Ferro E et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998; 83; 1917-1922.
80. Kimura H, Konishi K, Kaji M et al. Apoptosis, cell proliferation and expression of oncogenes in gastric carcinomas induced by preoperative administration of 5-fluorouracil. Oncol. Report 2000; 7; 971-976.
81. Nabeya Y, Loganzo F Jr, Maslak P et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer 1995; 64; 37-46.
82. Ozguroglu M, Demir G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1999; 86; 547-549.
83. Yukimoto K, Nakata B, Muguruma K et al. Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastric cancer cells with or without p53 mutation. Int. J. Oncol. 2001; 19; 373-378.